Citation(s)
- AVODART (Dutasteride 0
5 mg) Product Information. March 2011.
- Cai G, Thiessen JJ, Baidoo CA, Fossler MJ
Operating characteristics of a partial-block randomized crossover bioequivalence study for dutasteride, a drug with a long half-life: investigation through simulation and comparison with final results. J Clin Pharmacol. 2010 Oct;50(10):1142-50. doi: 10.1177/0091270009355155. Epub 2010 Feb 16.
- FLOMAX (Tamsulosin hydrochloride) Product Information
January, 2011.
- Food and Drug Administration (FDA)
Guidance for Industry: Handling and Retention of BA and BE Testing Samples. Centre for Drug Evaluation and Research, USA; 2004.
- GlaxoSmithKline Document Number 2011N112801_00 Study ID ARI114694
GlaxoSmithKline studyARI114694: An open-label, randomized, single dose, two-period cross-over study to determine the bioavailability of a fixed dose combination capsule formulation of duta
- GlaxoSmithKline Document Number HM2002/00171/01 Study ID ARI40005
A randomised, double-blind, parallel group study to investigate the efficacy and safety of treatment with Dutasteride (0.5mg) and Tamsulosin (0.4mg), administered once daily for 4 years, alone and in combination, on the improvement of symptoms and clinical outcome in men with moderate to severe symptomatic benign prostatic hyperplasia;. Report Date 09-Jul-2004.
- GlaxoSmithKline Document Number RM2001/00128/01 Study ID ARI10019
A Double-Blind, Placebo Controlled, Randomized, Parallel Group Study To Investigate The Changes In The Corrected QT Interval Following Repeat Oral Doses Of GI198745 In Healthy Male Volunte
- GlaxoSmithKline Document Number RM2003/00174/01 Study ID ARI10021
An Open-Label, Single Dose, 2-Way Cross-over Study to Investigate the Pharmacokinetics, Safety and Tolerability of oral Flomax (tamsulosin hydrochloride 0.4mg capsule-US) and Omnic (tamsul
- GlaxoSmithKline Document Number ZM2007/00022/00 Study ID ARI109882
An Open-Label, Randomized, Single Dose, Three-Period Cross-over Study to Determine the Bioequivalence and Food Effect of a Combination Capsule Formulation of Dutasteride and Tamsulosin Hy
- GlaxoSmithKline Document Number ZM2008/00126/02
Dutasteride Clinical Investigators Brochure v10. Report Date 27 May 2011.
- HARNAL (Tamsulosin hydrochloride 0
2 mg) Product Information. , 2011.
- HARNAL-D (Tamsulosin hydrochloride 0
2 mg) Product Information. , 2009.
- Matsushima H, Kamimura H, Soeishi Y, Watanabe T, Higuchi S, Tsunoo M
Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs, and humans. Drug Metab Dispos. 1998 Mar;26(3):240-5.
- McConnell JD
The long term effects of medical therapy on the progression of BPH: Results from the MTOPS Trial (abstract 1042). 167 (4):265, 2002. J. Urology. 2002;167 (4):265.
- Schuirmann DJ
A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987 Dec;15(6):657-80.
An Open-label, Randomized, Single Dose, Multi-stage, Cross-over Study to Determine the Relative Bioavailability of Fixed Dose Combination Products Containing a 3-oblong Dutasteride Soft Gel Capsule and Tamsulosin (0.5 mg Dutasteride /0.2 mg Tamsulosin HCl) Pellets Having a Range of Tamsulosin Release Rates Produced by Different Mixtures of Enteric Coated and Uncoated Pellets Relative to Harnal-D Tablets, in Healthy Male Subjects of North East Asian Ancestry.
Details for clinical trial NCT01495026
